SavedAdd your journal

Journals / Turkish Journal of Hematology / 2022 / Cilt: 39 - Sayı: 2

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation

Hematopoetik Kök Hücre Nakli Sonrası Trombositopeni Tedavisinde Eltrombopag Kullanımı

Leylagül KAYNAR
Ali ÜNAL
Mustafa ÇETİN
Bülent ESER
Zeynep Tuğba GÜVEN
Serhat ÇELİK
Pages
103–108
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median platelet count of the 23 responding patients was 12x109 /L (5-19x109 /L) before treatment and 68x109 /L (52-266x109 /L) after treatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to evaluate the efficacy and safety of eltrombopag (ELT) in the treatment of thrombocytopenia following hematopoietic stem cell transplantation (HSCT).
📊
Key Findings & Data:Materials and Methods: Forty-eight patients treated with ELT for thrombocytopenia after allogeneic or autologous transplantation at the Erciyes University Bone Marrow Transplantation Center between July 2017 and July 2021 were evaluated retrospectively.
💡
Conclusion & Impact:The median platelet count of the 23 responding patients was 12x109 /L (5-19x109 /L) before treatment and 68x109 /L (52-266x109 /L) after treatment (p
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to evaluate the efficacy and safety of eltrombopag (ELT) in the treatment of thrombocytopenia following hematopoietic stem cell transplantation (HSCT). Materials and Methods: Forty-eight patients treated with ELT for thrombocytopenia after allogeneic or autologous transplantation at the Erciyes University Bone Marrow Transplantation Center between July 2017 and July 2021 were evaluated retrospectively. Results: Forty-eight HSCT recipients were included in this study. Thirty (62.5%) patients were evaluated as having experienced delayed platelet recovery (DPR) and 18 (37.5%) patients as having experienced secondary failure of platelet recovery (SFPR). The median platelet count before ELT treatment was 13x109 /L (range: 3-20x109 /L). Twentythree patients responded to treatment and the cumulative incidence of successful platelet recovery was 48%. Patients with both DPR and SFPR responded, but patients with DPR had a higher response rate (50% vs. 44%). The median platelet count of the 23 responding patients was 12x109 /L (5-19x109 /L) before treatment and 68x109 /L (52-266x109 /L) after treatment (p

Özet

Amaç: Transplantasyon sonrası trombositopeni tedavisinde eltrombopagın (ELT) etkinlik ve güvenliğini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Erciyes Üniversitesi Kemik İliği Nakil Merkezi’nde Temmuz 2017-Temmuz 2021 tarihleri arasında allojenik veya otolog transplantasyon sonrası trombositopeni nedeniyle ELT ile tedavi edilen 48 hasta retrospektif olarak değerlendirildi. Bulgular: Bu çalışmaya 48 hematopoietik kök hücre nakli (HKHN) alıcısı dahil edildi. Otuz (%62,5) hasta gecikmiş trombosit iyileşmesi (DPR) ve 18 (%37,5) hasta ikincil trombosit iyileşme başarısızlığı (SFPR) olarak değerlendirildi. ELT tedavisinden önce medyan trombosit sayısı 13x109 /L (aralık, 3-20x109 /L) idi. Yirmi üç hasta tedaviye yanıt verdi ve başarılı trombosit iyileşmesinin kümülatif insidansı %48 idi. Hem DPR hem de SFPR’li hastalar yanıt verdi, ancak DPR’li hastalarda yanıt oranı daha yüksekti (%50’ye karşı %44). Yanıt veren 23 hastanın medyan trombosit sayısı tedaviden önce ve sonra 12 (5-19)x109 /L ve 68 (52- 266)x109 /L idi (p

🔖

Cite This Article

KAYNAR, L., ÜNAL, A., ÇETİN, M., ESER, B., GÜVEN, Z. T., ÇELİK, S. (2022). Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation. Turkish Journal of Hematology, Cilt: 39 - Sayı: 2, 103–108. https://ajindex.com/articles/606521

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kuzmina Z, Eder S, Böhm A, Pernicka E, Vormittag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012;26:746-756
  2. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, Nash RA. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:154-162
  3. Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y, Okamoto S. Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant 2006;38:377-384
  4. Dominietto A, Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Berisso G, Bregante S, Frassoni F, Casarino L, Verdiani S. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001;112:219-227
  5. Culligan D. Clinical bone marrow and blood stem cell transplantation. Br J Haematol 2001;112:254-255
  6. Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, Wentling V, Kalaycio M. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004;33:419- 423
  7. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247
  8. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171
  9. Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2015;2:e315-e325
  10. Mishra K, Pramanik S, Jandial A, Sahu KK, Sandal R, Ahuja A, Yanamandra U, Kumar R, Kapoor R, Verma T. Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res 2020;10:240
  11. Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X